Quick Look at Halozyme Therapeutics (HALO)

By Emilio Sanchez • Tuesday, March 14 12:09 • Permanent Link

Halozyme Therapeutics shares slid -2.61% this afternoon. Here's what you need to know about the mid-cap Biotechnology company:

Halozyme Therapeutics has logged a 24.12% 52 week change, compared to -9.54% for the S&P 500
HALO has an average analyst rating of buy and is -26.21% away from its mean target price of $56.63 per share
Its trailing earnings per share (EPS) is $1.45, which brings its trailing Price to Earnings (P/E) ratio to 28.82. The Health Care sector's average P/E ratio is 24.45
The company's forward earnings per share (EPS) is $3.79 and its forward P/E ratio is 11.03
The company has a Price to Book (P/B) ratio of 81.58 in contrast to the Health Care sector's average P/B ratio is 4.16
The current ratio is currently 5.65, which consists in its liquid assets divided by any liabilities due within in the next 12 months
The company's free cash flow for the last fiscal year was $235,300,000.00 and the average free cash flow growth rate is 107.15%
Halozyme Therapeutics's revenues have an average growth rate of 35.12% with operating expenses growing at 27.93%. The company's current operating margins stand at 41.72%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.